Clinical trial
Clobazam in Subjects With Lennox-Gastaut Syndrome
NCT00162981 · Lundbeck LLC, Industry · Completed
Key facts
| NCT number | NCT00162981 |
|---|---|
| Title | Clobazam in Subjects With Lennox-Gastaut Syndrome |
| Official title | Safety and Efficacy of Clobazam in Subjects With Lennox-Gastaut Syndrome |
| Lead sponsor | Lundbeck LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Epilepsy, Generalized, Seizures |
| Intervention type | Drug |
| Interventions | Clobazam Low Dose, Clobazam High Dose |
| Enrollment | 68 |
| Start date | Oct 1, 2005 |
| Primary completion | Aug 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Sep 13, 2005 |
| Last update posted | Feb 9, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: